Bluebird bio — Investor Presentation (January 2019)
74 slides from Bluebird bio's investor presentation, Jan 7, 2019
Slide 1: Making Hope A Reality – bluebird style
Making Hope A Reality – bluebird style January 2019 Exhibit 99.1
Slide 2: Forward-Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expre
Slide 3: Potential 2019 Catalysts
Potential 2019 Catalysts Lenti-D CALD Potential U.S./EU Filing LentiGlobin TDT EU Approval & First Launch Potential U.S. Filing 207 & 212 Data Update LentiGlobin SCD HGB-210 Study Start HGB-206 Group C Data Update bb2121 MM CRB-401 Data Update* KarMMa-1 Data Update* LentiGlobin TDT 207 & 212 Data Up
Slide 4: Radical Care: We Recode for Life
RADICAL CARE We care in a way that’s intense and truly sets us apart. WE RECODE FOR LIFE THIS IS PERSONAL Gene therapy is about saving lives one person at a time. And we are, each of us, personally all in. PIONEERS WITH PURPOSE We’re exploring new frontiers for the sake of patients.
Slide 5: We Live By Our Non-negotiables
We LIVE By Our Non-negotiables
Slide 6: Our 2022 Vision -- Just Got Bolder
T H E G E N E T H E R A P Y P R O D U C T S C O M P A N Y LentiGlobin SCD 2022 Potential Filing/Approval LentiGlobin TDT 2019 EU Potential Approval 2020 U.S. Potential Approval Lenti-D CALD 2020 Potential Approval bb2121 Multiple Myeloma 2020 Potential Approval Products on the Market 4 INDs per year
Slide 7: Unprecedented Opportunity: Anticipated Milestones
SCD: Potential Global LAUNCH MM: Earlier Line APPROVALS & LAUNCHES 2023+ SCD: U.S. & EU FILING/APPROVALS MM: Earlier Line Studies 2022 TDT: Label EXPANSION CALD: Global EXPANSION MM: Global EXPANSION in Relapsed/Refractory Earlier Line Studies 2021 TDT: EU Country EXPANSION U.S. APPROVAL & LAUNCH La
Slide 8: Recode the Science: R&D with Soul
RECODE THE SCIENCE: R&D with SOUL WHAT YOU SEE WHAT YOU DON’T SEE Internal Research Tools & Technology P13K Inhibition Enhanced Mftg TGF-B Flip CBL-B Edit DARIC Controls GAMMA DELTA Partners for Success T Cell megaTALs PRODUCT CANDIDATES PROGRAM AREA PRECLINICAL PHASE 1/2 PHASE 2/3 RIGHTS/PARTNER Se
Slide 9: Anti-Pure Play Principles - What Do We Mean?
Anti-Pure Play Principles - What Do We Mean? RECODING TRADITIONAL R&D 1:Many Target Strategy INTEGRATE ITERATE INTERNAL EXTERNAL Platform Tools & Technology R&D Enablers Clinical Insights MM - bb21217 SCD - BCL11a Liquid Tumor Programs Solid Tumor Programs SGD Programs TDT – LentiGlobin SCD – LentiG
Slide 10: Our Philosophy Applied in a Tumor Microenvironment
Our Philosophy Applied in a Tumor Microenvironment
Slide 11: Oncology Pipeline Enabled by Partners and Core Technologies
Oncology Pipeline Enabled by Our Partners and Our Core Technologies Two Academic Clinical Trial Starts Planned in 2019 20+ 2+ 15+
Slide 12: Research Strategy Yielding Emerging Oncology Pipeline
Research Strategy Yielding Emerging Oncology Pipeline PRECLINICAL DEVELOPMENT EARLY CLINICAL LATE CLINICAL TARGET VALIDATION 2020 & BEYOND: 1-2 INDs PER YEAR bb21217 MM bb2121 MM LentiGlobin TDT LentiGlobin SCD Lenti-D CALD BCL11A SCD Dual-targeted CAR Liquid tumor Next gen + megaTAL edit Binders, P
Slide 13: Recode the Systems: Anything But Traditional
RECODE THE SYSTEMS: ANYTHING BUT TRADITIONAL UNKNOWN IMPACT ONE-TIME POTENTIALLY CURATIVE OUR GOAL - MAKE IT SEAMLESS TO ALL STAKEHOLDERS Novel Science/Medicine Vector Production Bold & Balanced Access Model Supply Chain & Patient Management Drug Product Production
Slide 14: Platform Is Gearing Up for Launch
Virus Manufacturing Drug Product SCALABLE Clinical Data Real World Evidence to Support BLUE Style: Field Team Supply Chain Collecting Cells, Preparing, Shipping, Receiving Cells DELIVERY PLATFOM Platform Is Gearing Up for Launch TDT MAKE IT SEAMLESS
Slide 15: Preparing to Serve Patients in Europe in 2019
Preparing to Serve Patients in Europe in 2019 Apheresis Coordinator Apheresis Operator Cell Lab Operator Transplant Coordinator Transplant Nurse Transplant Physician Transplant Administrator bbb Manufacturing Logistics Apheresis Personnel Cell Lab Personnel Transplant Personnel (ATC) Manufacturer La
Slide 16: Value It: Time to Get It Right
Value It: Time to Get It Right Value we can PROVE? Value we can MODEL? Price of the LAST LAUNCH? Value Demonstration Analogue Assessment Pricing Environment What the MARKET will BEAR? What we can GET AWAY WITH? Pulse Checking The value our products bring to patients should stand on its own for all s
Slide 17: Value It: Value Based Payment Over Time
Value It : Quick Answer is Value Based Payment Over Time “Free Up” system to recognize value over time “Buy time” to prove enduring value Fix cost density constraint Fix policy constraints (e.g., best price) Fix “portability of cure” concern Heighten awareness of true unmet need in terms of impact o
Slide 18: Our Quest to Constantly Innovate Continues
Our Quest to Constantly Innovate Continues COLLABORATORS
Slide 19: Transfusion Dependent β-Thalassemia
Transfusion Dependent β-Thalassemia
Slide 20: Transfusion-Dependent β-Thalassemia (TDT)
Transfusion-Dependent β-Thalassemia (TDT) Inherited blood disease that requires lifelong, frequent blood transfusions and iron reduction therapy PROGRAM OVERVIEW Filed MAA with European Medicines Agency General regulatory agreement with FDA for BLA filing Studies ongoing: Northstar-2 (HGB-207) North
Slide 21: Transfusion-Dependent β-Thalassemia: Studies and Filing Basis
Transfusion-Dependent β-Thalassemia Basis of EU filing Original manufacturing process All genotypes Basis of EU and U.S. filings Refined manufacturing process Non-β0/β0 genotypes β0/β0 genotypes Refined manufacturing process HGB-204 HGB-207 HGB-212 Basis of EU filing (with Northstar) Original manufa
Slide 22: TDT Registration Strategy
PRIME ADAPTIVE PATHWAYS EU Pursue CONDITIONAL APPROVAL in patients with non-β0/β0 genotypes on the basis of data from ongoing Northstar (HGB-204) & HGB-205 studies, as well as available data from Northstar-2 (HGB-207) study US Pursue approval in adults and adolescents with non-β0/β0 genotypes based
Slide 23: Patients Free from Chronic RBC Transfusions
8/10 Patients with Non-β0/β0 Genotypes and 3/8 Patients with β0/β0 Genotypes are Free from Chronic RBC Transfusions 11.1 10.4 12.0 12.5 14.1 9.7 9.9 10.3 Time from treatment to last transfusion Time from last transfusion to last follow-up 9.1 10.3 10.9 Hb (g/dL) At last study visit Months Post Drug
Slide 24: 10/11 Patients Are Transfusion Free with Hemoglobin >11g/dL
10/11 Patients Are Transfusion Free with Hemoglobin >11g/dL *Male patients; ‡Hb supported by transfusions; †Weighted average Hb ≥9 g/dL without any RBC transfusions for ≥12 months; Hb, hemoglobin; VCN, vector copy number (vector copies/diploid genome) Data as of September 14, 2018 Time free from chr
Slide 25: High Levels of Gene Therapy Derived HbAT87Q
High Levels of Gene Therapy Derived HbAT87Q in 10/11 Patients *Male patients; ‡Patient is homozygous for IVS-I-5 β-globin mutation; ^Patient is heterozygous for IVS-I-5 β-globin mutation. Hb, hemoglobin. Transfused Data as of September 14, 2018 Transfused
Slide 26: Normal Total Hemoglobin in First Northstar-3 β0/β0 Patient
Normal Total Hemoglobin in First Northstar-3 β0/β0 Patient Data as of September 14, 2018 unless otherwise noted *Includes investigator reported data as of November 19, 2018, not from programmed statistical outputs AEs, adverse events; DP, drug product; Hb, hemoglobin; VCN, vector copy number (vector
Slide 27: Sickle Cell Disease
Sickle Cell Disease
Slide 28: Sickle Cell Disease (SCD)
Sickle Cell Disease (SCD) Severe blood disorder that causes anemia, frequent pain crises and shortened lifespan Global annual birth incidence ~ 300,000 – 400,000 Mean age of death in the U.S. is 44 years1 PROGRAM OVERVIEW Plan to pursue accelerated development path based on hematological primary end
Slide 29: Increasing Momentum to #ConquerSCD
Increasing Momentum to #ConquerSCD “Unfortunately, some treated [SCD] patients will have no reduction of their symptoms and the disease will continue to progress,” says Ann T. Farrell, M.D., director of the FDA’s Division of Hematology Products, CDER. “Better therapies are desperately needed,” Farre
Slide 30: SCD Studies and Accelerated Development Plan
Ongoing Phase 1/2, single arm, multi-center, U.S. study N=41 (Group C) Primary Endpoint: HbAT87Q and Total Hb Key Secondary Endpoint: Reduction in severe VOEs ≥12 years of age - ≤50 years of age Phase 1/2, single-center in France N=7 (4 β-thalassemia) HGB-205 (Transfusion-dependent b-thalassemia & s
Slide 31: HGB-206: Evolution of LentiGlobin in SCD
HGB-206: Evolution of LentiGlobin in SCD Bone Marrow Original Protocol and Manufacturing Process Bone Marrow Modified Protocol and Mixed Manufacturing Process Peripheral Blood Modified Protocol and Refined Manufacturing Process Medium Low Low Group A High Medium High Group C High High High Yes Group
Slide 32: Group C: Patient Characteristics
Group C: Patient Characteristics N=14 Patients Who Started Cell Collection Parameter Group C N=14 Age at consent median (min – max), years 25.5 (18 – 36) Gender 6 F 8 M Genotype βS/βS 14 Prior SCD History Hydroxyurea use, n 8 Recurrent VOCs*, n Annualized no. of events, median (min – max) 9 6.5 (3.5
Slide 33: Group C: Safety Profile Consistent with Myeloablative Busulfan Conditioning
Group C: Safety Profile Generally Consistent with Myeloablative Busulfan Conditioning Data as of September 14, 2018 Non-hematologic* grade ≥ 3 AEs Post-DP infusion in ≥2 patient n (%) N=9 Febrile neutropenia 6 (67) Stomatitis 6 (67) Serious AEs* Post-DP infusion in ≥1 patient n (%) N=9 Abdominal pai
Slide 34: Critical Elements of LentiGlobin Success in SCD
Critical Elements of LentiGlobin Success in SCD Fundamentally Improving Red Blood Cell Physiology 4 out of 4 patients with ≥47% anti-sickling Hb (range: 47% - 62%) at 6 months Sustained expression of HbAT87Q levels through 9 months follow-up High & Stable Levels of HbAT87Q Derived Hemoglobin & Total
Slide 35: Group C: Stable Peripheral Blood VCN, HbAT87Q Trajectory
Group C: Stable Peripheral Blood VCN, HbAT87Q Trajectory Robust and Consistent Data as of September 14, 2018 For Group A patients, medians (Q1, Q3) depicted; Group A patients with month 36 study visit (N=2)
Slide 36: Group C Patients Achieving Sickle Trait-like Hemoglobin Distribution
Group C Patients Achieving Sickle Trait-like Hemoglobin Distribution Data as of September 14, 2018 βS-globin decreasing with increasing HbAT87Q (average concentration of hemoglobin per cell has not changed post-treatment) Increase in βA-T87Q Results in Decrease in βS βS βA -T87Q βS Pre-Infusion Post
Slide 37: Impact on Clinical Outcomes of SCD in Group C
Impact on Clinical Outcomes of SCD in Group C Normalization of Key Biomarkers of Hemolysis Over Time Reticulocyte Counts Lactate Dehydrogenase Median (Q1, Q3) depicted Dot-dash lines denote lower and upper limits of normal values Data as of September 14, 2018 Total Bilirubin
Slide 38: LentiGlobin has Anti-Sickling Activity Comparable to Sickle Trait
Healthy Donor [AA] (n = 4) Sickle Trait [AS] (n = 12) Sickle Cell [SS] (n = 6) Hereditary Persistence of Fetal Hemoglobin with SS (n = 4)* *HbF levels in HPFH donors ranged from 28.1 to 42.3% Subject 206-114-1315 PB at 9 months post-infusion LentiGlobin has Anti-Sickling Activity Comparable to Sickl
Slide 39: Two Independent Assays Reveal Near Pancellular βA-T87Q Distribution
Two Independent Assays Reveal Near Pancellular βA-T87Q Distribution Majority of Patient RBCs are Positive for Anti-Sickling Globin 8.6% 91.4% Subject 1315 M9 Single Cell Western Subject 1315 M9 Flow Cytometry βS Healthy Donor (A/A) βS Sickle Cell Disease (S/S) βS βA or βA-T87Q 100% 100% A/S 100% Sic
Slide 40: Impact on Clinical Outcomes of SCD: Resolution of Anemia
Impact on Clinical Outcomes of SCD Resolution of Anemia (and Robust HbAT87Q Levels) in All Patients by 6 Months; No VOEs Since DP Infusion Data as of September 14, 2018 * Denotes female patients; ╪ Patient current receiving phlebotomy Group C: All patients free of VOEs as of data cut-off
Slide 41: A Case of Myelodysplastic Syndrome with Excess Blasts
A Case of Myelodysplastic Syndrome with Excess Blasts
Slide 42: Multiple Myeloma
Multiple Myeloma
Slide 43: Multiple Myeloma
Multiple Myeloma A lethal blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems and bone fractures BCMA PROGRAM OVERVIEW bb2121: Enrollment in KarMMa registration-enabling study complete (N=140) Additional studies advancing: KarMMa-2 in 2nd line Phase 2
Slide 44: CRB-401 Data at ASCO 2018 - Baseline Characteristics
CRB-401 Data at ASCO 2018 - Baseline Demographics and Clinical Characteristics Parameter Escalation (N=21) Expansion (N=22) Median (min, max) follow-up, d 345 (46, 638) 87 (29, 184) Median (min, max) age, y 58 (37, 74) 65 (44, 75) Male, n (%) 13 (62) 16 (73) Median (min, max) time since diagnosis, y
Slide 45: CRB-401 Data at ASCO 2018 - Heavily Pretreated Patient Population
Parameter Escalation (N=21) Expansion (N=22) Exposed Refractory Exposed Refractory Prior therapies, n (%) Bortezomib 21 (100) 14 (67) 22 (100) 16 (73) Carfilzomib 19 (91) 12 (57) 21 (96) 14 (64) Lenalidomide 21 (100) 19 (91) 22 (100) 18 (82) Pomalidomide 19 (91) 15 (71) 22 (100) 21 (96) Daratumumab
Slide 46: CRB-401 Data at ASCO 2018 - Tumor Response
CR, complete response; mDOR, median duration of response; ORR, objective response rate; PD, progressive disease; PR, partial response; sCR, stringent CR; VGPR, very good partial response. Data cut-off: March 29, 2018. 1Patients with ≥2 months of response data or PD/death within <2 months. ORR is def
Slide 47: CRB-401 Data at ASCO 2018 - Progression Free Survival
Data cut-off: March 29, 2018. Median and 95% CI from Kaplan-Meier estimate. NE, not estimable. 1PFS in dose escalation cohort. mPFS of 11.8 months at active doses (≥150 x 106 CAR+ T cells) in 18 subjects in dose escalation mPFS of 17.7 months in 16 responding subjects from all study cohorts who are
Slide 48: CAR T Treatment-Emergent Adverse Events
TEAE, n (%) Overall Grade ≥3 Cytokine release syndrome1 27 (63) 2 (5) Neurotoxicity2 14 (33) 1 (2) Neutropenia 35 (81) 34 (79) Thrombocytopenia 26 (61) 22 (51) Anemia 24 (56) 19 (44) Infection3 Overall First Month 26 (61) 10 (23) 9 (21) 2 (5) CAR T Treatment-Emergent Adverse Events All Infused Patie
Slide 49: Response to Current Standard of Care in Late Line RRMM
Response to Current Standard of Care in Late Line RRMM Chari, A. Blood 2017 43
Slide 50: bb2121 Patient Case: Months in sCR
bb2121 Patient Case: 21 Months in sCR General Information Age & Gender 52 year old Male Dose group 150x10^6 Tumor Burden High High Risk Cytogenetics (based on FISH) No Number of prior regimens 6 Initial diagnosis May, 2010 BCMA% (prescreen, baseline) 60, 75 VRD, Doxo VRD, M, ASCT K Pom bb2121 Durati
Slide 51: Advancing bb2121 into Earlier Lines of Multiple Myeloma
Advancing bb2121 into Earlier Lines of Multiple Myeloma Multiple Myeloma Trials planned in 2019 KarMMa 3 (MM-003) KarMMa 2 (MM-002) KarMMa (MM-001) Phase 3 Phase 2 Phase 1 Registration-enabling trial in late line enrollment complete Front line setting Phase 2 studies planned in 2019 3rd line+ Phase
Slide 52: Key Takeaways from CRB-401 Presented at ASCO
Key Takeaways from CRB-401 Presented at ASCO Efficacy? Durability? BCMA? MRD? Safety? Path forward? 95.5% ORR in doses above 150M cells. 50% CR rate at doses above 150M cells. 11.8 months median PFS in dose-escalation active doses. 17.7 months median PFS in MRD(-) patients with response (escalation
Slide 53: bb21217: PI3K Inhibition Drives Long-lived, Memory-like T Cells
Hypothesis: Increasing long-lived, memory-like T Cell subsets in the drug product may result in enhanced persistence of functional anti-BCMA CAR T cells in vivo TN Cell TSCM Cell TCM Cell TEM Cell TEFF Cell T Cell Plasticity Self Renewal Long-lived Terminally Differentiated No Self Renewal Short-liv
Slide 54: Preclinical Models: bb21217 Enriched for Memory-like T Cells
Preclinical Models: bb21217 is Enriched for Memory-like T Cells Exhibits; Enhanced Persistence of Anti-tumor Effect CD62L and CD27 are markers of memory-like T cells bb21217 is significantly enriched for T cells with this memory-like phenotype bb007 enhances anti-tumor effect in mouse models ONLY CA
Slide 55: CRB-402 Phase 1 Study Design and Status
CRB-402 Phase 1 Study Design and Status 3 + 3 dose escalationa 300 × 106 450 × 106 800 × 106 150 × 106 Collected N=13 Dosed N=12 (150 × 106 dose) HTBb n=6LTBb n=6 Study Status as of Oct 18, 2018 Median (min, max) follow-up 26 wk (4, 51) Primary endpoints: AEs, DLTs Other endpoints: Responsec, PFS, O
Slide 56: CRB-402 Safety: CRS and Adverse Events
CRS occurred in 67% of patients Mostly grade 1/2, 1 grade 3, no grade 4 Median time to onset of CRS 4.5 days (2,11) Manageable with or without tocilizumab 1 patient experienced DLT (grade 4 encephalopathy and grade 3 CRS) Patient had high tumor burden and rapidly accelerating disease at baseline No
Slide 57: Clinical Data Early But Consistent with Enhanced Persistence
Clinical Data is Early But Consistent with Goal of Enhanced Persistence Robust and reliable bb21217 CAR T cell expansion post-infusion observed at first dose Early bb21217 clinical data is consistent with robust functional CAR T cell persistence Enrichment for memory-like CAR T cells observed in pre
Slide 58: Clinical Responses Observed in 10/12 Patients at First Dose Level
Clinical Responses Observed in 10/12 Patients (83%) at First Dose Level Tested (150 x 106 CAR+ T cells) Data as of October 18, 2018 b b a Clinical Responses Over Time CR, complete response; MRD, minimal residual disease; PR, partial response; VGPR, very good partial response. *Patients with high tum
Slide 59: High Clinical Response Rate Observed at First Dose Level
High Clinical Response Rate Observed at First Dose Level (150 x 106 CAR+ T cells) Clinical Response bb21217-Treated (N=12) ORR,a n (%) [95% CI] 10 (83.3) [51.6, 97.9] sCR/CR 3 (25) ≥VGPR 6 (50) MRD status in bone marrow, n MRD-evaluable respondersb 4 MRD-neg 4c Median time to first response (min, ma
Slide 60: Promising Early Data with Next-Generation Anti-BCMA CAR T
Promising Early Data with Next-Generation Anti-BCMA CAR T bb21217 demonstrated promising early clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma at first dose level tested 83% ORR with 90% of responses ongoing Elimination of MRD in the bone marrow of all 4 ev
Slide 61: CALD
CALD
Slide 62: Cerebral Adrenoleukodystrophy
Cerebral Adrenoleukodystrophy Severe, often fatal neurological disease in boys UNMET NEED Treatment limited to allo-HSCT Sometimes severe treatment-related risks and complications, especially when donor is not a matched sibling EPIDEMIOLOGY Global incidence of ALD: 1 in ~21,000 newborns Cerebral for
Slide 63: Lenti-D Treatment Halts CALD Disease Progression
Lenti-D Treatment Halts CALD Disease Progression 15/17 patients (88%) alive and MFD-free at 24 months follow-up; all patients continue to be MFD-free as of April 25, 2018 Exceeds pre-determined efficacy benchmark for the study MFD-free survival in 13/15 (76%) 12 additional patients treated in Starbe
Slide 64: Recent Collaborations
Recent Collaborations
Slide 65: Science-Driven and Highly Complementary Partnership
Science-Driven and Highly Complementary Partnership BLUE remains BLUE: Clear value proposition through product rights, shared funding and capabilities Science: best-in-class technology platforms joining forces to crush cancer Culture: science- and patient-focused companies with a willingness to push
Slide 66: Engaging the Right Target with the Optimal Target Binder
Engaging the Right Target with the Optimal Target Binder Pick Great Targets Fully Human CARs Identify Human TCRs Better Models …rapid generation of genetically engineered mice ...fully human antibodies through immunization …rapid identification & preclinical testing of target specific antibodies …fu
Slide 67: Partnership Highlights
Partnership Highlights Share costs equally through pre-IND research and into Phase 1/2 development For 50/50 collaboration products, development and commercialization costs (by region) are shared equally bluebird funds development and commercialization of its wholly-owned products $100 million equit
Slide 68: Gritstone Complements bluebird's Approach to Oncology Therapeutics
Gritstone complements bluebird’s approach to generating novel therapeutics for oncology Patient biopsy Tumor targets TCR Cell therapy Patient therapy gritstone Routine clinical biopsy gritstone Mass spec validation of expressed tumor targets in patients and sequencing of tumor transcriptome Select p
Slide 69: Early Pipeline
Early Pipeline
Slide 70: BLUE Toolbox Strategy
Good Is Never Good Enough For Patients: BLUE Toolbox Strategy Product Engine Novel areas; autoimmune In vivo gene editing Optimized severe genetic disease products New & enhanced oncology products Transduction Durability BCMA (bb2121) LentiGlobin BCMA & PI3Ki (bb21217) LentiGlobin & Enhancers v1.0 v
Slide 71: Initial Proof of Concept: LVV Approach to Suppression of BCL11a in SCD
Initial Proof of Concept: LVV Approach to Suppression of BCL11a in SCD As of July 28, 2018, one patient had received treatment with HSCs transduced with an LVV encoding the BCL11a shRNAmiR As of day 76: Sustained Hb of >10 g/dL 59.7% total HbF cells; 30% HbF as a fraction of all β-like globin Notabl
Slide 72: CBLB Knock-out Enhances CAR-T Cell Anti-tumor Activity
CBLB Knock-out Enhances CAR-T Cell Anti-tumor Activity Novel Technology for Improving T Cell Function in Liquid and Solid Tumors 2 3 1 CBLB megaTAL induces a high rate of gene editing and corresponding knockdown of CBLB protein levels CBLB megaTAL treatment enhances production of cytokines in vitro
Slide 73: ASH Highlights: Next Generation Programs / Platforms
ASH Highlights: Next Generation Programs / Platforms First clinical demonstration of the potential to genetically manipulate HbF levels through BCL11a Novel LVV expressing a shRNAmiR to knock down BCL11a at the level exclusively in erythroid cells Robust knock down of BCL11a observed in patient cell
Slide 74: Go TRUE BLUE: We Must Make Hope a Reality
Go TRUE BLUE We Must Make Hope a Reality